Celemics, a Korean manufacturer of targeted capture kits for next-generation sequencing, is combining its bioinformatics pipeline with analytics technology from Strand Life Sciences to help researchers go from sample to report using a single technology platform.
Under terms of the partnership, Bengaluru, India-based Strand Life Sciences will integrate the Celemics pipeline into its StrandOmics tertiary analysis platform. This integrated offering will include assay-specific variant filters to provide “guaranteed” clinical-grade data compliance for researchers in cancer and rare diseases, according to the companies.
Strand Life Sciences is a global bioinformatics and genomic profiling company established in 2000. Strand Life Sciences, formed from the business combination of Strand and Triesta, the diagnostics unit of HCG, is India’s leading specialized diagnostics company. Its expertise spans strong global bioinformatics and clinical research capabilities with a pan-India presence in specialised and routine diagnostics services.